Immunoglobulin G1, Anti-(Human Interleukin 1.Beta.) (Human Clone Acz885 Heavy Chain V Region)
Mevalonate Kinase Deficiency
Explore 1 assets in Mevalonate Kinase Deficiency →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01303380CT.gov Canakinumab in Patients With Active Hyper-IgD Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mevalonate Kinase Deficiency
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Interleukin 1.Beta.) (Human Clone Acz885 Heavy Chain V Region) (this asset) | Novartis Pharmaceuticals | P2 | CCC · 54 |
Other indications for Immunoglobulin G1, Anti-(Human Interleukin 1.Beta.) (Human Clone Acz885 Heavy Chain V Region)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Systemic-Onset Juvenile Idiopathic Arthritis | — | P3 | BB · 64 |
| Hereditary Periodic Fever Syndrome | — | P3 | B · 58 |
| COVID-19 | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Interleukin 1.Beta.) (Human Clone Acz885 Heavy Chain V Region) in Mevalonate Kinase Deficiency. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-interleukin-1beta-human-clone-acz885-heavy-chain-v-region-mevalonate-kinase-deficiency
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →